2023-08-04 03:47:39 ET
- Korea Institute of Toxicology have decided to implement Certara’s ( NASDAQ: CERT ) Pinnacle 21 Enterprise data conformance and submission software and SEND Explorer pre-clinical data visualization software .
- The combination of Pinnacle 21 Enterprise and SEND Explorer enables synergy for meeting global regulatory guidelines and delivering efficiency.
- “We expect that using Pinnacle 21 Enterprise will help KIT increase the quality of SEND Datasets for submission to regulatory agencies. In addition, SEND Explorer will help KIT provide advanced analysis including historical data and cross-analysis studies of toxicity tests, that enable sponsors to quickly address questions from the FDA.” said Junyong Lee, Korea Country Sales Director at Certara.
For further details see:
Certara up 4% on collaboration with Korea Institute of Toxicology